Introduction {#sec1_1}
============

Plantar warts are a common viral skin disease caused by human papillomavirus (HPV) infection \[[@B1]\]. HPV has a specific tropism for squamous stratified epithelium \[[@B2]\] and this infection leads to proliferation of keratinocytes. HPV infection is characterized by a relevant immune evasion mechanism that inhibits and delays the host immune response to the virus \[[@B3]\]. HPV genotypes types 2, 4, 27, 57, and 60 are responsible for common and plantar warts and myrmecia \[[@B4]\]. On the other hand, genotypes 6 and 11 are the most common HPV involved in genital wart \[[@B5]\] development. Curettage, topical salicylic acid, and cryotherapy are often used in plantar warts \[[@B6]\]. Liquid nitrogen is the most frequently used treatment for this type of warts; however, this procedure is in general very painful \[[@B7]\]. Excision is not a good option owing to frequent recurrences or scarring \[[@B8]\]. In case of therapy-resistant lesions, laser and photodynamic therapy approaches could be used \[[@B9]\] but these methods are time- and cost-consuming. Therefore, in case of plantar warts, both first- and second-line treatments are in general still unsatisfactory due to their low efficacy, low local tolerability, and high recurrence rate \[[@B10]\]. Topical green tea extract containing catechins (Polyphenon E) is indicated as a first-line treatment for genital warts (condylomata acuminata) \[[@B11]\]. In subjects with genital warts, Polyphenon E, applied 3 times a day and up to 16 weeks, induced a complete clearance rate in more than 50% of patients \[[@B12]\]. In addition, the recurrence rate at 3 months after the conclusion of the therapy is as low as \< 6% \[[@B9]\]. Polyphenon E is a quantified extract of green tea leaves (*Camellia sinensis*) where the main active substance is epigallocatechin gallate (EGCG), a polyphenol substance which represents the major component of the catechins fraction \[[@B13]\]. EGCG has potent anti-inflammatory, antioxidant, and proapoptotic actions. These mechanisms could explain its antiviral properties \[[@B14]\]. Recent data have shown that EGCG is able to modulate the cellular genes involved in Toll-like receptor production and in the apoptosis mechanisms \[[@B15]\]. The product has shown a good safety and tolerability profile. Local skin reactions like erythema and edema, in general mild to moderate, have been reported in most treated subjects \[[@B16]\]. Polyphenon E has shown to be an effective and very well-tolerated treatment for common \[[@B17]\] and plane \[[@B18]\] warts. Data regarding the efficacy of Polyphenon E in plantar warts are lacking so far. We report the clinical efficacy and the tolerability of Polyphenon E 10% ointment (Veregen^TM^, Medigene, Germany) in a subject with a "difficult-to-treat", treatment-resistant plantar wart.

Case Description {#sec1_2}
================

A 67-year-old immunocompetent nonsmoking man presented with a large mosaic plantar wart on his right foot. The lesion had been present for 5 years. Several cryotherapy sessions (a total of 6 procedures) had been performed with no success. The lesion was therefore treated with a 5-fluorouracil regimen and then with a topical combination of 5-fluorouracil and salicylic acid, but also these approaches failed. At the initial visit, a large (16 cm^2^) mosaic wart lesion was present (Fig. [1](#F1){ref-type="fig"}). Treatment with topical Polyphenon E 10% twice daily was prescribed and started. After 3 months of treatment, the lesion completely disappeared (Fig. [2](#F2){ref-type="fig"}). Interestingly, no curettage or mechanical pickling of the hyperkeratotic parts of the lesion were performed before the start of the treatment. Local tolerability was evaluated as very good by the patient.

Discussion {#sec1_3}
==========

Plantar warts account for 30% of all cutaneous warts \[[@B19]\]. Large lesions are in general plaques with rough hyperkeratotic surface with some brown-black dots representing thrombosed capillaries \[[@B20]\]. These lesions could be very painful, especially if the lesion is located over pressure sites such as the metatarsal head \[[@B21]\]. Plantar wart treatment remains a challenging therapeutic problem \[[@B22]\]. Some procedures could be very painful with a long downtime posttreatment period \[[@B23]\]. Polyphenon E ointment is considered an effective, well-tolerated, self-applicable topical treatment of genital warts \[[@B24]\]. Clinical efficacy and tolerability was evaluated in randomized vehicle-controlled phase III trials in more than 1,000 patients \[[@B25]\]. Complete clearance rate is observed in 51% of the treated subjects. Mean treatment duration for complete clearance was between 14 and 16 weeks \[[@B26]\]. Polyphenon E has an antiviral action trough pathway triggering cell growth arrest and increasing proapoptotic molecules like p53 and p16 \[[@B27]\]. In addition, this compound interferes with cellular activity of E6 and E7, two HPV virus proteins \[[@B28]\]. E6 and E7are involved in the process of apoptosis inhibition and in the immune evasion mechanisms \[[@B29]\]. Therefore, Polyphenon E could express anti-HPV action through multiple mechanisms. The gene modulation expressed by Polyphenon could be of help in fighting therapy-resistant HPV lesions. Polyphenon E has shown to be an effective treatment of plane warts of the face \[[@B30]\]. An ideal wart therapy should be easy to apply (preferably home-based), painless, able to resolve all the treated lesions, not causing scarring, and with no or very short downtime period \[[@B23]\]. In this case report, we have shown a high clinical efficacy of Polyphenon E in the treatment of a therapy-resistant large mosaic plantar wart lesion. It is remarkable that complete clearance of the lesion was achieved with a 12-week treatment without any pretreatment curettage or pickling procedures and without a downtime period and without scar formation. This case report suggests that topical Polyphenon E 10% could be an effective therapeutic strategy in subjects with "difficult-to-treat" plantar wart lesions. Specific controlled trials in this specific population are warranted.
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